Janssen Signs Deal with PeptiDream

April 7, 2017

Janssen will have access to PeptiDream’s proprietary Peptide Discovery Platform System technology, which will be used to identify peptides against multiple metabolic and cardiovascular targets.

Biopharmaceutical company PeptiDream, headquartered in Tokyo, Japan announced that it has entered into a multi-target discovery and optimization collaboration with Janssen Pharmaceuticals. Under the agreement, Janssen will have access to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. The platform will be used to identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen, and to optimize hit peptides into therapeutic peptides or small molecule products.

Janssen will hold an exercisable option to peptide-drug conjugate (PDC) use and applications. Janssen will also have the right to develop and commercialize all compounds resulting from this collaboration.

In return, PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.15 billion. In addition, PeptiDream will be entitled to royalties on sales of any products that arise from the collaboration.

Source: PeptiDream